World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 26 June 2012
Main ID:  EUCTR2011-004820-37-ES
Date of registration: 15/02/2012
Prospective Registration: Yes
Primary sponsor: Fundación FISEVI
Public title: Experimental study in humans to evaluate the efficacy and safety of blood products rich in proteins for the treatment of anal fistulas in Crohn's patients
Scientific title: Phase II, open-label clinical trial to evaluate the safety and efficacy of platelet-rich plasma and fibrin clot processed with PRGF-System tecnology in the treatment of anal fistulas in Crohn's patients
Date of first enrolment: 13/06/2012
Target sample size:
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-004820-37
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no Number of treatment arms in the trial: 1  
Phase: 
Countries of recruitment
Spain
Contacts
Name: Clara M. Rosso Fernández   
Address:  Avda. Manuel Siurot s/n 41013 Seville Spain
Telephone: 34955013414
Email: claram.rosso.sspa@juntadeandalucia.es
Affiliation:  UCICEC-Hospital Virgen del Rocío
Name: Clara M. Rosso Fernández   
Address:  Avda. Manuel Siurot s/n 41013 Seville Spain
Telephone: 34955013414
Email: claram.rosso.sspa@juntadeandalucia.es
Affiliation:  UCICEC-Hospital Virgen del Rocío
Key inclusion & exclusion criteria
Inclusion criteria:
Age 18 or over / Confirmed diagnosis of Crohn's disease a year before
the inclusion date / Presence of perianal fistula / Identifiable internal
orifice / Demonstration activity of the fistulizing perianal pathology
based on clinical (including PDAI) and radiological (pelvic MRI and
endoanal ultrasound) criteria / Presence of 3 or less fistulous tracts / No
inflamatory activity in the rectum or proctitis (confirmed by
colonoscopy) / Written informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
Superficial fistulas whose treatment of choice is fistulotomy / Presence
of more than 3 fistulous tracts / Rectourethral and rectovaginal fistulas
/ Endoanal abscesses larger than 2 cm detected by physical examination
or imaging (pelvic MRI endoanal ultrasound) / Current anorectal tumors
/ Clinically significant anal fissures or stenosis which prevent the
rectoscopy or similar procedures / Impossibility of performing MRI for
any reason (prosthesis, contrast allergy, claustrophobia ...) /
Impossibility of performing endoanal ultrasound for any reason /
Clinically inactive fistulizing disease (including PDAI) / Pregnant
women or women in the first 6 months post-partum / Chemotherapy
performed in the 6 months prior to study inclusion/ Bleeding diathesis or
concurrent anticoagulant therapy / Prior
radiation with evidence of radiation injury in the treatment area /
Participation in any clinical trial during the 3 months prior to the
screening visit / Other serious conditions or bio-psycho-social factors
that may predict lack of compliance with study procedures / Major
surgery or serious trauma of the subject in the previous semester /
Congenital or acquired immunodeficiencies / Presence of surgical
threads, unless they can be removed before starting treatment / Severe
proctitis (striking friability, spontaneous bleeding, multiple erosions,
deep ulcers), judging by the sigmoidoscopy / Malignancy in remission
for less than a years before study inclusion, with the exception of basal
cell carcinoma (BCC).


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Perianal fistulas in Crohn's Disease Patients
MedDRA version: 14.1 Level: LLT Classification code 10068659 Term: Perianal fistula System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders
Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
Intervention(s)

Product Name: Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología PRGF-System (BTI)
Pharmaceutical Form: Rectal solution
INN or Proposed INN: Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología PRGF-System (BTI)
Other descriptive name: HUMAN PLASMA FOR FRACTIONATION
Concentration unit: % percent
Concentration type: equal
Concentration number: 100-

Primary Outcome(s)
Secondary Objective: Secondary objectives: To evaluate the efficacy in terms of ratio of
complex perianal fistula closure, decrease in the number of draining
fistulas after two consecutive visits, and
percentage of subjects with healed fistula (measured by MRI).
Main Objective: Main objective: To evaluate the safety and feasibility of intralesional
platelet-rich plasma and fibrin clot from autologous origin, processed with PRGF-System tecnology (BTI), for the treatment of perianal fistulas in Crohn's disease.
Primary end point(s): Incidence of IMP-related adverse events during a follow-up period of 12
months post-treatment.
Timepoint(s) of evaluation of this end point: Weeks 0, 2, 12, 22, 24, 36, 46 and 48.
Secondary Outcome(s)
Secondary end point(s): 1. Ratio of complex perianal fistula closure in Crohn's disease patients,
after 24 and 48 weeks of follow-up.
2. Number of draining fistulas after two consecutive visits at weeks 22,
24 and 46, 48.
3. Percentage of subjects with healed fistula (measured by MRI) after 12
and 24 weeks of follow-up.
Timepoint(s) of evaluation of this end point: Weeks 0, 2, 12, 22, 24, 36, 46 and 48.
Secondary ID(s)
PRGF/AF/2011
Source(s) of Monetary Support
Consejería de Salud (Junta de Andalucía)
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history